We are focused on building a better future for patients by developing a portfolio of differentiated and transformational therapeutics for patients with serious and life-threatening diseases. We have a track record of successful collaborations that demonstrate our commitment to speed, innovation, and strong partner relationships. To date, we have acquired the rights to 4 compounds currently in development and are keenly interested in expanding our pipeline with novel, differentiated programs and platforms. Interested in partnering with us? Contact us today!
We are particularly interested in modalities, technologies or drug platforms that enable:
- Inducing immune tolerance
- Biomarker-based approaches to stratifying patients within larger heterogeneous diseases
- Combination therapeutics
Treating inflammatory or orphan/niche cardiovascular conditions
- Rapid development potential from concept to IND
- Bioinformatic approaches to identify potential disease targets or responder populations